Department of Veterans Affairs, Office of Research and Development (VA)

Agency/Department

FLC Region

Security Lab

No

Address

810 Vermont Ave (NW)
Washington, DC 20420
United States

Laboratory Representative

Description

 

VA’s Research and Development program (VA Research), with its distinguished history of discovery and innovation dating back to 1925, today remains an essential part of VA’s efforts to ensure the health and wellbeing of our nation’s Veterans. The fundamental mission of VA Research is to advance the health and care of Veterans. It is part of the Veterans Health Administration, America’s largest integrated health care systems with over 1,700 sites of care, serving 8.3 million Veterans each year. With a state of-the-art electronic health record, VA Research is uniquely positioned to conduct pioneering research.

 

With the unique combination of accessible data, a national research setting with linked infrastructure, and a large research population, VA Research is renowned for conducting large-scale clinical trials and comparative effectiveness research. With more than 70 percent of VA researchers also providing care to patients, the program is poised to quickly move innovations and discoveries from the research setting to the care setting. Findings from clinical research, considered with findings from genomics and health services research, VA Research provides evidence-based information that can be used to enhance VA’s ability to provide personalized health care, care tailored to a specific patient’s circumstances. By giving VA providers such evidence-based information about an intervention’s effectiveness, the research helps guide providers as they consider various health care options and inform patients to participate in care decisions.

Mission

The Office of Research and Development (ORD) aspires to discover knowledge, develop VA researchers and health care leaders, and create innovations that advance health care for our Veterans and the Nation. ORD is headquartered in Washington, DC and has an estimated 3,000 investigators and 10,000 research staff located at 119 VA Medical Centers (VAMCs around the country. VA Research is an intramural research program that also embraces its close ties with academic affiliates, other federal agencies, nonprofit organizations, and private industry. By partnering with others who have common research interests, VA Research is able to leverage resources and expand the impact of federal research investments.

ORD consists of four research services that together form a cohesive whole to explore all phases of veterans' healthcare needs. Each Service oversees a number of world renowned research centers nationwide.

The Biomedical Laboratory Research & Development Service conducts research that explores basic biological or physiological principles in humans or animals but does not involve intact human beings. For example, it includes research on animal models and investigations of tissues, blood or other biologic specimens from humans

The Clinical Science Research and Development Service conducts research that focuses on intact human beings as the unit of examination. Examples include interventional and effectiveness studies, clinical, epidemiological and technological studies.

The Health Services Research and Development Service pursues research at the interface of health care systems, patients and health care outcomes. HSR&D underscores all aspects of VA health care; specifically quality, access, patient outcomes and health care costs.

The Rehabilitation Research & Development Service is dedicated to the well-being of America's veterans through a full spectrum of research: from approved rehabilitation research projects, through evaluation and technology transfer to final clinical application.

Each of these four services is headed by a director who is supervised by the Chief Research and Development Officer (CRADO), who in turn reports to the Deputy Under Secretary for Health for Policy and Services.

Technology Disciplines

Technologies
Displaying 1 - 10 of 281
 
A System and Method for Positioning and Supporting an Exercise Machine for use in a Hospital Bed (M-PACE)
A High Current, Radio Frequency Coupled Microstimulator for Autonomic Applications
A Surgically Implantable Urinary Incontinence Device
Acridone compounds
Acridone compounds
Activating extraction of demineralized bone matrix
Activation of quiescent stem cells
Acyl CoA:cholesterol acyltransferase (ACAT-2)
Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome
Alpha B-crystallin as a therapy for ischemia or inflammation

Pages

Facilities

No Facilities

Equipment

No Equipment

Programs

No Programs

Funds

No Funds

Publications

No Publications

Awards

No Awards

Successes

No Successes

Licenses
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateFeb 26, 2021

The present invention relates to the use of Cyclo-Z to stimulate cell growth and immune system components, and to modulate levels of several components involved in inflammation and autoimmune diseases, which may be helpful in fighting infectious agents as well as be useful in treating allergies, inflammation, and autoimmune diseases.

Dates:
Comments must be received by March 15, 2021
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Dr. Lee A. Sylvers, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (813) 505-6989 (this is not a toll-free number), Email: lee.sylvers@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention to NovMetaPharma Co., Ltd. as they have submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent to Exclusive License
Publication DateFeb 17, 2021

Mobile isolation device that protects health-care workers from aerosolized pathogens while treating a patient. The device surrounds the head of the bed and the patient's head and chest. It can easily be moved from one bed to another. It height is adjustable.

Dates:
February 17, 2021
Address:
Department of Veterans Affairs Technology Transfer Program (14RDTT) 810 Vermont Ave, NW Washington, DC 20420 Office: 202-443-5609
For further information contact:

David Marks

Supplementary information:
Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent to license exclusively
Publication DateFeb 03, 2021

Electric wheelchair

Dates:
February 3, 2021 through February 19, 2021
Address:
Department of Veterans Affairs Technology Transfer Program Office of Research and Development (RD14TT) 810 Vermont Avenue, NW. Washington, DC 20420
For further information contact:

David Marks (david.marks2@va.gov)

Supplementary information:

Potential Licensee is MEBot LLC

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent to license exclusively
Publication DateFeb 03, 2021

Epo-derived peptide has neuro-protective activity

Dates:
February 3, 2021 through February 19, 2021
Address:
Department of Veterans Affairs Technology Transfer Program (RD14TT) Office of Research and Development 810 Vermont Avenue, NW. Washington, DC 20420
For further information contact:

David Marks (david.marks2@va.gov)

Supplementary information:

Belum Therapeutics requested exclusive license

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateJan 25, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Griffon Pharmaceuticals Inc., 7140 Alfred Nobel, Montreal, QC H4S 2C1, Canada an exclusive license to U.S. Patent Application No. 16/611,147 and PCT/US2018/031261, associated with VA Invention Disclosure number 2016-145 titled, “Methods and Composition for Treating Liver Disease”.

Dates:
Comments must be received on or before February 10, 2021.
Address:
Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov
For further information contact:

Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as Griffon Pharmaceuticals, Inc. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateJan 20, 2021

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to ePurines, Inc, 650 Komas Drive, Suite 104A, Salt Lake City, UT 84108, USA, an exclusive license to U.S. Patent No. 10,107,795 and U.S. Patent No. 10,024,846 associated with VA Invention Disclosure number 13-239 titled, “Composition and Methods for the Prevention and Treatment of Diet Induced Obesity”.

Dates:
Comments must be received on or before February 3, 2021.
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 255-0613 (this is not a toll-free number), patricia.cullum@va.gov.
For further information contact:

Send comments to Ms. Patricia A. Cullum, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 255-0613 (this is not a toll-free number), patricia.cullum@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as ePurines, Inc. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateDec 09, 2020

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to exci, Corp., 415 U St. NW, Washington, DC 20001, USA an exclusive license to U.S. Patent Nos. 9,320,907 and 10,201,703, U.S. Patent Application Nos. 16/229,530, 16/549,743, 63/007,596 and 63/080,904, and International Patent Application No. PCT/US2019/047864, associated with VA Invention Disclosure numbers 10-049, 2020-129 and 2020-376, respectively titled, “Integrated surface stimulation device for pain management and wound therapy”, “Flexatrode”, and, “AFTIDerm”.

Dates:
Comments must be received on or before December 24, 2020.
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as exci, Corp. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateNov 25, 2020

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Sports Engineering Inc., 126 Daniel Street, Suite 300, Portsmouth, NH 03801, USA an exclusive license to U.S. Provisional Patent Application No. 63/079,270, associated with VA Invention Disclosure number 2020-520 titled, “Face Mask with Transparent Portion”, or also known as “Clear Talker Mask”.

Dates:
Comments must be received on or before December 11, 2020.
Address:
Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420
For further information contact:

Send comments to Mr. Stefan Susta, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (937) 409-7993 (this is not a toll-free number), Email: stefan.susta@va.gov

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as Sports Engineering, Inc. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateOct 29, 2020

Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to UNYQ, Inc., 2193 Fillmore St., San Francisco, CA 94115, USA an exclusive license to International Patent Application No. PCT/US2019/037513, associated with VA Invention Disclosure number 2017-074 titled, “Prosthetic ankle assembly and ankle-foot system comprising same”.

Dates:
Comments must be received on or before November 16, 2020.
Address:
Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.
For further information contact:

Send comments to Mr. Ryan Davis, Technology Transfer Specialist, Office of Research and Development (10X2TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 632-7554 (this is not a toll-free number), ryan.davis7@va.gov.

Supplementary information:

The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as UNYQ, Inc. has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Correction:
Send Inquiry
Agency
Department of Veterans Affairs, Office of Research and Development (VA)
Action:
Intent
Publication DateMay 13, 2020

Heated pulse oximeter US Patent 9,795,332 and U.S. Patent Application No. 15/698,370

Dates:
May 13, 2020
Address:
Office of Research and Development (10X2TT) Department of Veterans Affairs 810 Vermont Avenue, NW. Washington, DC 20420
For further information contact:

David Marks
david.marks2@va.gov
202-443-5609

Supplementary information:
Correction:
Send Inquiry

Pages